Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.70 USD
Change Today -0.29 / -4.84%
Volume 478.5K
ECYT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

endocyte inc (ECYT) Snapshot

Open
$5.95
Previous Close
$5.99
Day High
$6.01
Day Low
$5.65
52 Week High
09/10/14 - $9.35
52 Week Low
01/22/15 - $5.01
Market Cap
239.0M
Average Volume 10 Days
374.5K
EPS TTM
$0.12
Shares Outstanding
41.9M
EX-Date
--
P/E TM
47.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDOCYTE INC (ECYT)

endocyte inc (ECYT) Related Businessweek News

No Related Businessweek News Found

endocyte inc (ECYT) Details

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial in recurrent prostate cancer patients. The company is also developing EC1788, a folate receptor-targeted SMDC that is in preclinical development stage to treat cancer; EC1669, which is in preclinical development stage to treat inflammatory diseases; and EC0371 that is in preclinical development stage for the treatment of polycystic kidney disease. In addition, it develops Etarfolatide, a companion imaging agent for its SMDCs that target folate receptor; and EC0652, a diagnostic imaging agent targeting prostate-specific membrane antigen. The company has a collaboration agreement with Merck Sharp & Dohme Research GmbH for the development and commercialization of Vintafolide. Endocyte, Inc. was founded in 1995 and is headquartered in West Lafayette, Indiana.

81 Employees
Last Reported Date: 03/13/15
Founded in 1995

endocyte inc (ECYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $475.6K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $208.7K
Chief Financial Officer and Chief Operating O...
Total Annual Compensation: $323.0K
Vice President of Research
Total Annual Compensation: $278.5K
Vice President of Clinical Operations
Total Annual Compensation: $261.8K
Compensation as of Fiscal Year 2014.

endocyte inc (ECYT) Key Developments

Endocyte, Inc. Appoints P. David Mozley, M.D. as Vice President of Imaging

Endocyte, Inc. announced that P. David Mozley, M.D. has been appointed as vice president of imaging. Prior to joining Endocyte, he served as professor and chief of the Division of Nuclear Medicine at Weill Cornell Medical College and the New York Presbyterian Hospital/Weill Cornell Campus in Manhattan.

Endocyte, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Endocyte, Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $12,000 compared to $17,274,000 a year ago. Loss from operations was $8,187,000 compared to $2,963,000 a year ago. Net loss was $8,081,000 compared to $2,902,000 a year ago. Basic and diluted loss per share was $0.19 compared to $0.08 a year ago. For the year, the company reported collaboration revenue of $70,353,000 compared to $64,871,000 a year ago. Income from operations was $5,026,000 compared to loss from operations of $18,342,000 a year ago. Net income was $5,459,000 compared to net loss of $18,032,000 a year ago. Basic and diluted earnings per share were $0.13 compared to basic and diluted loss per share of $0.50 a year ago.

Endocyte, Inc., Q4 2014 Earnings Call, Mar 02, 2015

Endocyte, Inc., Q4 2014 Earnings Call, Mar 02, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECYT:US $5.70 USD -0.29

ECYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECYT.
View Industry Companies
 

Industry Analysis

ECYT

Industry Average

Valuation ECYT Industry Range
Price/Earnings 45.8x
Price/Sales 3.6x
Price/Book 1.2x
Price/Cash Flow 46.0x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOCYTE INC, please visit www.endocyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.